ANG Lifesciences India Limited (BOM:540694)
India · Delayed Price · Currency is INR 35.73
-0.21 (-0.58%)
At close: Jul 27, 2026
ANG Lifesciences India Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Revenue Revenue Growth | 862.13 | 928.47 | 1,461 | 2,199 | 3,543 | 1,544 |
Revenue Growth | -24.28% | -36.45% | -33.55% | -37.94% | 129.50% | 21.72% |
Gross Profit Gross Profit Growth | 287.39 | 332.24 | 509.97 | 693.01 | 1,263 | 504.18 |
Operating Income Operating Income Growth | -78.99 | -72.97 | 13.78 | 134.63 | 618.6 | 126.57 |
Net Income Net Income Growth | -117.64 | -124.13 | -101.43 | -2.62 | 403.17 | 70.28 |
Earnings Per Share EPS Growth | -9.00 | -9.51 | -7.77 | -0.20 | 31.11 | 5.42 |
EPS Growth | - | - | - | - | 473.69% | 15.29% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Pharmaceuticals Pharmaceuticals Growth | 864.7 | 899.1 | 1,314 | 2,070 | 3,487 | 1,544 |
Printing and Packagings Printing and Packagings Growth | 34.97 | 67.63 | 183.02 | 242.05 | 218.97 | - |
Inter Segment Inter Segment Growth | -37.54 | -38.27 | -35.61 | -113.19 | -162.65 | - |
Total Total Growth | 862.13 | 928.47 | 1,461 | 2,199 | 3,543 | 1,544 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Cash & Investments Cash & Investments Growth | 35.79 | 36.36 | 57.35 | 61.78 | 66.52 | 38.63 |
Total Debt Total Debt Growth | 898.74 | 832.06 | 728.37 | 707.48 | 769.95 | 431.61 |
Net Cash (Debt) Net Cash Growth | -862.95 | -795.7 | -671.01 | -645.71 | -703.43 | -392.98 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -66.04 | -60.93 | -51.39 | -49.70 | -54.28 | -30.33 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | - | -2.56 | -94.95 | 263.77 | 247.17 | 91.44 |
Capital Expenditures CapEx Growth | - | -37.51 | -55.69 | -104.45 | -413.45 | -42.44 |
Free Cash Flow Free Cash Flow Growth | - | -40.07 | -150.63 | 159.33 | -166.28 | 49 |
Free Cash Flow Growth | - | - | - | - | - | 53.66% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Gross Margin | 33.34% | 35.78% | 34.90% | 31.52% | 35.65% | 32.66% |
Operating Margin | -9.16% | -7.86% | 0.94% | 6.12% | 17.46% | 8.20% |
Pretax Margin | -18.32% | -16.91% | -7.33% | 1.19% | 15.10% | 6.57% |
Profit Margin | -13.64% | -13.37% | -6.94% | -0.12% | 11.38% | 4.55% |
FCF Margin | - | -4.32% | -10.31% | 7.25% | -4.69% | 3.17% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 28, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
PE Ratio | - | - | - | - | 6.03 | 6.33 |
P/FCF Ratio | 16.75 | - | - | 6.23 | - | 9.08 |
PS Ratio | 0.55 | 0.32 | 0.40 | 0.45 | 0.69 | 0.29 |